JP2013515748A5 - - Google Patents

Download PDF

Info

Publication number
JP2013515748A5
JP2013515748A5 JP2012546257A JP2012546257A JP2013515748A5 JP 2013515748 A5 JP2013515748 A5 JP 2013515748A5 JP 2012546257 A JP2012546257 A JP 2012546257A JP 2012546257 A JP2012546257 A JP 2012546257A JP 2013515748 A5 JP2013515748 A5 JP 2013515748A5
Authority
JP
Japan
Prior art keywords
virus
influenza
particle
envelope
influenza antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012546257A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013515748A (ja
JP6073031B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/062217 external-priority patent/WO2011090712A2/en
Publication of JP2013515748A publication Critical patent/JP2013515748A/ja
Publication of JP2013515748A5 publication Critical patent/JP2013515748A5/ja
Application granted granted Critical
Publication of JP6073031B2 publication Critical patent/JP6073031B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012546257A 2009-12-28 2010-12-28 インフルエンザ抗原のエンベロープウイルスベースのウイルス様粒子溶液を安定化させる方法 Expired - Fee Related JP6073031B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29043809P 2009-12-28 2009-12-28
US61/290,438 2009-12-28
PCT/US2010/062217 WO2011090712A2 (en) 2009-12-28 2010-12-28 Methods for stabilizing influenza antigen enveloped virus-based virus-like particle solutions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016193457A Division JP2016222722A (ja) 2009-12-28 2016-09-30 インフルエンザ抗原のエンベロープウイルスベースのウイルス様粒子溶液を安定化させる方法

Publications (3)

Publication Number Publication Date
JP2013515748A JP2013515748A (ja) 2013-05-09
JP2013515748A5 true JP2013515748A5 (cg-RX-API-DMAC10.html) 2014-01-09
JP6073031B2 JP6073031B2 (ja) 2017-02-01

Family

ID=44307476

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012546257A Expired - Fee Related JP6073031B2 (ja) 2009-12-28 2010-12-28 インフルエンザ抗原のエンベロープウイルスベースのウイルス様粒子溶液を安定化させる方法
JP2016193457A Pending JP2016222722A (ja) 2009-12-28 2016-09-30 インフルエンザ抗原のエンベロープウイルスベースのウイルス様粒子溶液を安定化させる方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016193457A Pending JP2016222722A (ja) 2009-12-28 2016-09-30 インフルエンザ抗原のエンベロープウイルスベースのウイルス様粒子溶液を安定化させる方法

Country Status (4)

Country Link
US (2) US20130028933A1 (cg-RX-API-DMAC10.html)
EP (1) EP2519539A4 (cg-RX-API-DMAC10.html)
JP (2) JP6073031B2 (cg-RX-API-DMAC10.html)
WO (1) WO2011090712A2 (cg-RX-API-DMAC10.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103316356B (zh) * 2012-03-22 2016-08-17 北京三诺佳邑生物技术有限责任公司 一种重组慢病毒载体制剂
US10137186B2 (en) * 2013-03-14 2018-11-27 Takeda Vaccines, Inc. Compositions and methods for live, attenuated alphavirus formulations
EP3082769B1 (en) * 2013-12-19 2018-01-31 Janssen Vaccines & Prevention B.V. Improved formulations for virosomes
US10100093B2 (en) * 2013-12-31 2018-10-16 Epitopix Llc Polypeptides and immunizing compositions containing Burkholderia polypeptides and methods of use
EP3270960A4 (en) * 2015-03-20 2018-08-08 Bluebird Bio, Inc. Vector formulations
AU2016355323B2 (en) 2015-11-19 2021-03-04 Novartis Ag Buffers for stabilization of lentiviral preparations
US12065482B2 (en) * 2016-08-10 2024-08-20 Celltrion Inc. Stable liquid pharmaceutical formulation of anti-influenza virus antibody
JPWO2019021957A1 (ja) * 2017-07-25 2020-07-09 第一三共株式会社 点鼻用乾燥粉末医薬組成物
US20210008195A1 (en) * 2017-12-20 2021-01-14 Zoetis Services Llc Vaccines against hendra and nipah virus infection
US11523988B2 (en) * 2018-11-29 2022-12-13 Catalent U.K. Swindon Zydis Limited Oral dispersible vaccine comprising virosomes

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2505657A1 (fr) * 1981-05-13 1982-11-19 Pasteur Institut Perfectionnements apportes aux agents de stabilisation de virus vivants pour la preparation de vaccins, et vaccins stabilises contenant lesdits agents de stabilisation
EP0775495B1 (en) * 1995-11-25 2001-03-07 Study Center of Allergy Projects (S.C.A.P.) Use of a disaccharide as stabilizer for liquid protein mixtures and liquid protein mixtures containing a disaccharide
US6616931B1 (en) * 1996-09-26 2003-09-09 Merck & Co., Inc. Rotavirus vaccine formulations
ATE376059T1 (de) * 2000-06-23 2007-11-15 Wyeth Corp Assemblierung von wildtyp und chimären influenzavirus-ähnlichen partikeln (vlps)
AU2001280934A1 (en) * 2000-07-28 2002-02-13 Alliance Pharmaceutical Corp. Methods and compositions to upregulate, redirect or limit immune responses to bioactive compounds
US20100221284A1 (en) * 2001-05-30 2010-09-02 Saech-Sisches Serumwerk Dresden Novel vaccine composition
US20060088909A1 (en) * 2002-05-17 2006-04-27 Compans Richard W Virus-like particles, methods of preparation, and immunogenic compositions
KR20050088175A (ko) * 2002-12-17 2005-09-02 메드이뮨 백신즈 인코포레이티드 생물활성 물질의 고압 분무 건조
US20060257852A1 (en) * 2003-04-10 2006-11-16 Chiron Corporation Severe acute respiratory syndrome coronavirus
GB0313916D0 (en) * 2003-06-16 2003-07-23 Glaxosmithkline Biolog Sa Vaccine composition
CN101124343A (zh) * 2004-04-01 2008-02-13 阿尔扎公司 用于经皮肤输送流感疫苗的装置和方法
PA8661401A1 (es) * 2005-01-28 2006-09-08 Wyeth Corp Formulaciones del liquido polipeptido estabilizado
WO2007044610A2 (en) * 2005-10-07 2007-04-19 Avatar Vaccines, Inc. Virus-like particles and methods of use
EP1878791A1 (en) * 2006-07-11 2008-01-16 Bia Separations D.O.O. Method for influenza virus purification
CA2658393A1 (en) * 2006-07-21 2008-01-24 The Regents Of The University Of California Human endogenous retrovirus polypeptide compositions and methods of use thereof
EP2044198A4 (en) * 2006-07-27 2010-09-08 Ligocyte Pharmaceuticals Inc CHIMERIC INFLUENZA VIRUS TYPE PARTICLES
WO2008061243A2 (en) * 2006-11-16 2008-05-22 Novavax, Inc. Respiratory syncytial virus-virus like particle (vlps)
EP2254593B1 (en) * 2008-02-21 2018-09-05 Biological Mimetics, Inc. Immunogenic influenza composition
EP2254554A1 (en) * 2008-02-25 2010-12-01 Novavax, Inc. Sugar glassified virus like particles (vlps)
KR20120131725A (ko) * 2011-05-26 2012-12-05 건국대학교 산학협력단 고병원성 조류인플루엔자 ａ ｈ５ｎ１ 바이러스 유사입자 및 이를 이용한 가금용 백신
CA2863949C (en) * 2012-02-13 2021-06-29 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Computationally optimized broadly reactive antigens for human and avian h5n1 influenza

Similar Documents

Publication Publication Date Title
Wang et al. Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases
US20230390381A1 (en) Immunogenic combinations
JP7311489B2 (ja) 異種ｒｅｐＲＮＡ免疫化のための方法および組成物
US12440550B2 (en) Immunogenic compositions and uses thereof
Rossey et al. Vaccines against human respiratory syncytial virus in clinical trials, where are we now?
Simnani et al. COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review
JP2014503206A5 (cg-RX-API-DMAC10.html)
JP2023081859A (ja) コロナウイルスワクチン
JP2020528911A5 (cg-RX-API-DMAC10.html)
TW201343669A (zh) 抗ｒｓｖ疫苗
JP2012501959A5 (cg-RX-API-DMAC10.html)
JP2009539965A5 (cg-RX-API-DMAC10.html)
CN107106673A (zh) 用于增强免疫应答的方法和组合物
Quan et al. Progress in the development of virus-like particle vaccines against respiratory viruses
US20250000968A1 (en) Sars-cov-2 spike fused to a hepatitis b surface antigen
CN121038810A (zh) 针对冠状病毒感染、流行性感冒感染和/或rsv感染的组合疫苗
AU2014302282A1 (en) Methods and compositions for dengue virus vaccines
CN116650633A (zh) 冠状病毒疫苗
JP2024523329A (ja) ウイルス性疾患用の温度制御可能な自己複製ｒｎａワクチン
JP4797149B2 (ja) インフルエンザウイルスに対するベクターワクチン
Wong et al. Influenza vaccination: options and issues
Gattinger et al. Fusion protein-based COVID-19 vaccines exemplified by a chimeric vaccine based on a single fusion protein (W-PreS-O)
Lupascu et al. Achievements and Challenges in Therapy and Vaccines Development of Viral Hemorrhagic Fevers: An Up-to-Date Review
Jiang et al. Aggregation by peptide conjugation rescues poor immunogenicity of the HA stem
Lundstrom COVID-19 Vaccines: Where Do We Stand at the End of 2023?